Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence
Hepatitis C virus infection can lead to chronic active hepatitis, cirrhosis, and liver failure; however, it is also associated with a wide range of extra-hepatic complications. HCV is associated with a large spectrum of histopathological lesions in both native and transplanted kidneys, and it is inc...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Scientifica |
| Online Access: | http://dx.doi.org/10.6064/2012/128382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553690875035648 |
|---|---|
| author | Fabrizio Fabrizi |
| author_facet | Fabrizio Fabrizi |
| author_sort | Fabrizio Fabrizi |
| collection | DOAJ |
| description | Hepatitis C virus infection can lead to chronic active hepatitis, cirrhosis, and liver failure; however, it is also associated with a wide range of extra-hepatic complications. HCV is associated with a large spectrum of histopathological lesions in both native and transplanted kidneys, and it is increasingly recognized as an instigator of B cell lympho-proliferative disorders including mixed cryoglobulinemia. Mixed cyoglobulinemia is a systemic vasculitis primarily mediated by immune complexes; it is characterized by variable organ involvement including skin lesions, chronic hepatitis, glomerulonephritis, peripheral neuropathy, and arthralgias. The most frequent HCV-associated nephropathy is type I membranoproliferative glomerulonephritis, usually in the context of type II mixed cryoglobulinemia. Various approaches have been tried for the treatment of HCV-related glomerulonephritis, including immunosuppressive therapy (corticosteroids and cytotoxic agents), plasma exchange and antiviral agents. Data on the antiviral treatment of HCV-associated glomerulonephritis are not abundant but encouraging results have been provided. Immunosuppressive therapy is particularly recommended for cryoglobulinemic kidney disease. Recent evidence has been accumulated on rituximab therapy for HCV-related cryoglobulinemic glomerulonephritis exists but several questions related to its use remain unclear. Distinct approaches should be considered for the treatment of HCV-associated cryoglobulinemic glomerulonephritis according to the level of proteinuria and kidney failure. |
| format | Article |
| id | doaj-art-804e9be7a94743238500227c4a9a39af |
| institution | Kabale University |
| issn | 2090-908X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Scientifica |
| spelling | doaj-art-804e9be7a94743238500227c4a9a39af2025-02-03T05:53:32ZengWileyScientifica2090-908X2012-01-01201210.6064/2012/128382128382Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel EvidenceFabrizio Fabrizi0Division of Nephrology and Dialysis, Maggiore Hospital and IRCCS Foundation, Pad. Croff, Via Commenda 15, 20122 Milano, ItalyHepatitis C virus infection can lead to chronic active hepatitis, cirrhosis, and liver failure; however, it is also associated with a wide range of extra-hepatic complications. HCV is associated with a large spectrum of histopathological lesions in both native and transplanted kidneys, and it is increasingly recognized as an instigator of B cell lympho-proliferative disorders including mixed cryoglobulinemia. Mixed cyoglobulinemia is a systemic vasculitis primarily mediated by immune complexes; it is characterized by variable organ involvement including skin lesions, chronic hepatitis, glomerulonephritis, peripheral neuropathy, and arthralgias. The most frequent HCV-associated nephropathy is type I membranoproliferative glomerulonephritis, usually in the context of type II mixed cryoglobulinemia. Various approaches have been tried for the treatment of HCV-related glomerulonephritis, including immunosuppressive therapy (corticosteroids and cytotoxic agents), plasma exchange and antiviral agents. Data on the antiviral treatment of HCV-associated glomerulonephritis are not abundant but encouraging results have been provided. Immunosuppressive therapy is particularly recommended for cryoglobulinemic kidney disease. Recent evidence has been accumulated on rituximab therapy for HCV-related cryoglobulinemic glomerulonephritis exists but several questions related to its use remain unclear. Distinct approaches should be considered for the treatment of HCV-associated cryoglobulinemic glomerulonephritis according to the level of proteinuria and kidney failure.http://dx.doi.org/10.6064/2012/128382 |
| spellingShingle | Fabrizio Fabrizi Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence Scientifica |
| title | Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence |
| title_full | Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence |
| title_fullStr | Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence |
| title_full_unstemmed | Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence |
| title_short | Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence |
| title_sort | hepatitis c virus cryoglobulinemia and kidney novel evidence |
| url | http://dx.doi.org/10.6064/2012/128382 |
| work_keys_str_mv | AT fabriziofabrizi hepatitiscviruscryoglobulinemiaandkidneynovelevidence |